分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Inducible caspase-9 suicide gene under control of endogenous oct4 to safeguard mouse and human pluripotent stem cell therapy

Yang Liu, Yang Yang, Yangyang Suo, Chuan Li, Min Chen, Shuwen Zheng, Hao Li, Chengcheng Tang, Nana Fan, Ting Lan, Jizeng Zhou, Yingying Li, Jiaowei Wang, Huangyao Chen, Qingjian Zou, Liangxue Lai

Journal:Molecular Therapy-Methods & Clinical Development

IF:5.85

DOI:10.1016/j.omtm.2022.01.014

PMID:35229007

Published:2022-02-01

research field:合成生物学消化生物学肝脏病学

Abstract

Pluripotent stem cells (PSCs) are promising in regenerative medicine. A major challenge of PSC therapy is the risk of teratoma formation because of the contamination of undifferentiated stem cells. Constitutive promoters or endogenous SOX2 promoters have been used to drive inducible caspase-9 ( iCasp9 ) gene expression but cannot specifically eradicate undifferentiated PSCs. Here, we inserted iCasp9 gene into the endogenous OCT4 locus of human and mouse PSCs without affecting their pluripotency. A chemical inducer of dimerization (CID), AP1903, induced iCasp9 activation, which led to the apoptosis of specific undifferentiated PSCs in vitro and in vivo . Differentiated cell lineages survived because of the silence of the endogenous OCT4 gene. Human and mouse PSCs were controllable when CID was administrated within 2 weeks after PSC injection in immunodeficient mice. However, an interval longer than 2 weeks caused teratoma formation and mouse death because a mass of somatic cells already differentiated from the PSCs. In conclusion, we have developed a specific and efficient PSC suicide system that will be of value in the clinical applications of PSC-based therapy.

本文使用的Yeasen产品

购物车
客服
转染试用